Jan 2026 $26 M Private placement after listing $10 to $50 million 7
iBio, Inc.: Private sale, Jan 2026 × Investors in this round 7 investors had bought by the notice of Jan 22, 2026: 7 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $26 M of $26 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $1,560,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Felipe A. Duran · Executive Officer Marc A. Banjak · Executive Officer Martin A. Brenner · Executive Officer, Director Alexandra A. Kropotova · Director Antonio A. Parada · Director David A. Arkowitz · Director Evert A. Shimmelpennink · Director Gary A. Sender · Director William A. Clark · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Oppenheimer & Co. Inc. (CRD 000000249) · New York, New York Sold in CA, CT, IL, MA, NY LifeSci Capital LLC (CRD 000168404) · New York, New York Sold in CA, CT, IL, MA, NY Leerink Partners LLC (CRD 000039011) · Boston, Massachusetts Sold in CA, CT, IL, MA, NY Remarks in the notice On fees: “The total sales commission will be divided among the three placement agents as follows: 75% to Leerink Partners LLC, 12.5% to LifeSci Capital LLC and 12.5% to Oppenheimer & Co. Inc.”On the amounts: “Does not include the proceeds to be received upon the cash exercise of pre-funded warrants issued in the private placement at an exercise price of $0.001 per share.”On the use of proceeds: “While no offering proceeds are set aside for payments to named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers.”Signed by Marc Banjak, Chief Legal Officer. Source: SEC Form D, newest notice filed Jan 22, 2026. Read the notice at the SEC .
options SEC Apr 2025 $11 M Private placement after listing $10 to $50 million 5
iBio, Inc.: Private sale, Apr 2025 × Investors in this round 5 investors had bought by the notice of May 7, 2025: 5 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $11 M of $11 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $217,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Felipe A. Duran · Executive Officer Marc A. Banjak · Executive Officer Martin A. Brenner · Executive Officer, Director Alexandra A. Kroptova · Director Antonio A. Parada · Director David A. Arkowitz · Director Evert A. Shimmelpennink · Director Gary A. Sender · Director William A. Clark · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Chardan Capital Markets LLC (CRD 000120128) · New York, New York Sold in GA, MA, NY, PR, TX Remarks in the notice On the amounts: “Includes $0.125 per share received upon sale of warrants and $0.86 per share that may be received upon future exercise of warrants”On the use of proceeds: “While no offering proceeds are set aside for payments to named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers.”Signed by Marc Banjak, Chief Legal Officer. Source: SEC Form D, newest notice filed May 7, 2025. Read the notice at the SEC .
options SEC Mar 2024 $15 M Private placement after listing $10 to $50 million 8
iBio, Inc.: Private sale, Mar 2024 × Investors in this round 8 investors had bought by the notice of Apr 4, 2024: 8 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $15 M of $15 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, other: Warrants and Pre-Funded Warrants Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $794,124
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Felipe Duran · Executive Officer Martin Brenner · Executive Officer Alexandra Kropotova · Director Evert Shimmelpennink · Director Gary Sende · Director James Hill · Director Linda Armstrong · Director William Clark · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Chardan Capital Markets LLC (CRD 000120128) · New York, New York Sold in GA, MA, NY, PR, TX Remarks in the notice On the use of proceeds: “While no offering proceeds are set aside for payments to named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers.”Signed by Martin Brenner, Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 4, 2024. Read the notice at the SEC .
equity, options SEC Jan 2016 $2 M Private placement after listing $2 to $10 million 1
iBio, Inc.: Private sale, Jan 2016 × Investors in this round 1 investor had bought by the notice of Feb 3, 2016: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue $1 million to $5 million
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Mark Giannone · Executive Officer · Chief Financial Officer Robert Erwin · Executive Officer · President Robert Kay · Executive Officer · Executive Chairman and Chief Executive Officer Terence Ryan · Executive Officer · Chief Scientific Officer Arthur Elliott · Director Glenn Chang · Director James Hill · Director John McKey · Director Philip Russell · Director Seymour Flug · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Robert B. Kay, Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 3, 2016. Read the notice at the SEC .
equity SEC Oct 2010 $7 M No. 2 $2 to $10 million 52
iBio, Inc.: Raise no. 2, Oct 2010 × Investors in this round 52 investors had bought by the notice of Nov 10, 2010: 51 accredited, 1 not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $7 M of $8 M offered; $1 M still to sell
Smallest investment taken $5,000
What was sold equity, options or other rights to buy securities
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions $560,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and finders' fees as estimates
The company Corporation, incorporated in Delaware People named in the notice Frederick Larcombe · Executive Officer · Chief Financial Officer Robert Kay · Director, Executive Officer · Chief Executive Officer Glenn Chang · Director JOHN McKEY · Director James Hill · Director Pamela K. Bassett · Director Philip K. Russell · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Noble International Investments, Inc. (CRD 15768) · Boca Raton, Florida Sold in FL, GA, IL, MD, NC, NY, SC, VA Remarks in the notice On fees: “Sales commissions of 7% shall be paid to the Placement Agent. To date, the Placement Agent has been paid $494,550.”Signed by Robert B. Kay, Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 10, 2010. Read the notice at the SEC .
equity, options SEC Sep 2009 $3 M No. 1 $2 to $10 million 26
iBio, Inc.: Raise no. 1, Sep 2009 × Investors in this round 26 investors had bought by the notice of Sep 23, 2009: 26 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $3 M offered
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $159,381
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Frederick Larcombe · Executive Officer Geoffrey Schild · Executive Officer Robert Erwin · Executive Officer Robert Kay · Executive Officer, Director Glenn Chang · Director James T. Hill · Director John D Mckey · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Noble Financial Capital Markets (CRD 15768) · Boca Raton, Fl Sold in all US states Signed by Frederick Larcombe, Cfo. Source: SEC Form D, newest notice filed Sep 23, 2009. Read the notice at the SEC .
equity SEC